Safety and tolerability of oral islatravir (ISL) once-monthly (QM) as pre-exposure prophylaxis (PrEP) in cisgender men and transgender women at elevated risk for acquiring HIV-1

Conference Reports for NATAP

HIVR4P 2024
5th HIV Research for
Prevention Conference
Lima, Peru - Oct 6-10 2024


Safety and tolerability of oral islatravir (ISL) once-monthly (QM) as pre-exposure prophylaxis (PrEP) in cisgender men and transgender women at elevated risk for acquiring HIV-1

	Raphael J. Landovitz